1Masahiro,Inoue,Masahisa.Nakada,et al.Structure Elucidation and Enantioselective Total Synthesis of the Potent HMG-CoA Reductase Inhibitor FR901512 via Catalytic Asymmetric Nozaki-Hiyama Reactions[J].J Am Chem Soc,2007,129(14):4164 -4165.
2Hidetaka H,Bunji S,Ikuko S.FR901512,a Novel HMG-CoA Reductase Inhibitor Produced by an Agonomycetous Fungus No.14919[J].J Antibiot.,2004,57(6):390 -393.
3Sime RJ,Marschner IC,Hunt D.Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Provastatin in Ischemic Disease(LIPID),Trial[J].Circulation.,2002; 105:1162- 1169.
5Thomas Pearson,Christie Ballantyne,Christine Sisk.Comparison of Effects of Ezetimibe/Simvastatin Versus Simvastatin Versus Atorvastatin in Reducing C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels[J].The American Journal of Cardiology,2007,Available online 2 May.
6Christie Ballantyne,Michael A Blazing,Thomas R King.Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia[J].The American Journal of Cardiology,2004,93(12):1487 - 1494.
7Christie Ballantyne,Robert Weiss,Tiziano Moccetti.Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study)[J].The American Journal of Cardiology,2007,99(5):673 -680.
8Jean-Francois Dorval,Todd Anderson,Jean Buithieu.Reaching recommended lipid and blood pressure targets with amLodipine/atorvastatin combination in patients with coronary heart disease[J].The American Journal of Cardiology,2005,95 (2):249 - 253.
9Peter Sever,Bjornn Oahlof,Neil Poulter.Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial[J].Eur Heart J.2006,27:2982 - 2988.
10James M.McKenney,Peter H.Jones,Harold E.Bays.Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)[J].Atherosclerosis,2007,192(2):432 -437.
二级参考文献17
1Rosenhlum SB, Huynh T, Afonso A, et al. Disoovery of 1-(4-fluropheny1 )-( 3R )-[ 3- (4-fluorophenyl) -3 S-hydroxypropy1 ]-(4S )-(4-hydroxypropy1 )-2-azetidinone ( SCH 58235 ) : a designed, potent,orally active inhibitor of cholesterol absorption [ J ]. J Med Chem,1998, 41(6) :973 - 980.
2Rudel LL. Preclinical and clinical pharmacology of a new class of lipid management agents[J]. Am J Manag Care, 2002, 8(2 Suppl) :S33 - S37.
3Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans[J]. Circulation, 2005, 111(18):2356-2363.
4Davis HR Jr, Zhu I J, Hoos LM, et al. Niemann-Piek C1 like 1(NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis [ J ]. J Biol Chem, 2004, 279(32) :33586 - 33592.
5Smart EJ, De Rose RA, Father SA. Annexin-2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport[J].Proc Natl Acad Sci USA, 2004, 101 (10) : 3450 - 3455.
6Valasek MA, Weng J, Shaul PW, et al. Caveolin-1 is not required for murine intestinal cholesterol transport [ J ]. J Biol Chem, 2005,280(30) :28103 - 28109.
7Frick W, Bauer-Schafer A, Bauer J, et al. Synthesis of a biotintagged photoaffinity probe of 2-azetidinone cholesterol absorption inhibitors[J]. Bioorg Med Chem, 2003, 11(8) :1639- 1642.
8Kramer W, Girbig F, Corsiero D, et al. Aminopeptidase N (CD13)is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane[J]. J Biol Chem, 2005,280(2) : 1306 - 1320.
9Harry RD Jr, Douglas SC, Lizbeth H, et al. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in apoE knockout mice arteriosclerosis [ J ]. Thromb Vasc Biol, 2001, 21:2032 - 2038.
10Davis HR Jr, Ptda KK, Alton KB, et al. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor,ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs [ J ]. Metabolism, 2001, 50 (10) :1234- 1241.
